Literature DB >> 11741994

Tumor-derived osteopontin is soluble, not matrix associated.

Susan R Rittling1, Yanping Chen, Fei Feng, Yiming Wu.   

Abstract

The secreted phosphoprotein osteopontin (OPN), when immobilized on a surface, supports cell adhesion, prevents apoptosis of endothelial cells, and is a ligand for the alpha(v)beta(3) integrin, which is important in endothelial cell biology and neovascularization. OPN synthesized by tumor cells stimulates tumor growth, but the mechanism by which the protein acts remains unclear. One possibility, therefore, is that OPN may exert its effects on tumor growth by enhancing angiogenesis. While OPN is found at high levels in bone, where it is a component of the mineralized matrix, we have asked here whether OPN present in tumors is similarly extracellular matrix associated. We have shown that OPN is detectable in tumor extracts and in serum of tumor-bearing mice, and that the protein in tumors and in serum can be synthesized by both tumor and the host cells. Biochemical fractionation of tumor tissue confirmed that there is little if any association of OPN with the insoluble fraction. Immunochemical analysis of murine mammary tumors shows no co-localization of OPN with the extracellular matrix, identified by laminin staining. Ras-transformed cells in culture produce abundant OPN, however, the protein was found to be associated with the cell fraction but not with the matrix fraction. An enzyme-linked immunosorbent assay was used to demonstrate that OPN in conditioned medium from these cells fails to associate with extracellular matrix components, including laminin and fibronectin, in vitro. Recombinant OPN (GST-OPN) when coated onto a plastic surface can support human umbilical vein endothelial cell adhesion, suppressing apoptosis and allowing cell cycle progression, at concentrations from 1 to 50 microg/ml. Soluble GST-OPN in the same concentration range has no effect on HUVECs held in suspension. Thus, we conclude that OPN associated with tumors is primarily soluble, and that soluble OPN can neither support endothelial cell proliferation nor prevent apoptosis of these cells in the absence of adhesion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11741994     DOI: 10.1074/jbc.M109028200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Override of the osteoclast defect in osteopontin-deficient mice by metastatic tumor growth in the bone.

Authors:  Tajneen Natasha; Misty Kuhn; Owen Kelly; Susan R Rittling
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

2.  Host-derived osteopontin maintains an acute inflammatory response to suppress early progression of extrinsic cancer cells.

Authors:  Yu-Hua Hsieh; M Margaret Juliana; Kang-Jey Ho; Hui-Chien Kuo; Henri van der Heyde; Craig Elmets; Pi-Ling Chang
Journal:  Int J Cancer       Date:  2011-10-20       Impact factor: 7.396

Review 3.  Osteopontin: an effector and an effect of tumor metastasis.

Authors:  L A Shevde; S Das; D W Clark; R S Samant
Journal:  Curr Mol Med       Date:  2010-02       Impact factor: 2.222

4.  Modulation of infection-mediated migration of neutrophils and CXCR2 trafficking by osteopontin.

Authors:  Rani Singh; Tommy Hui; Aritsune Matsui; Ziyad Allahem; Christopher D Johnston; Montserrat Ruiz-Torruella; Susan R Rittling
Journal:  Immunology       Date:  2016-10-07       Impact factor: 7.397

5.  Osteopontin binding to the alpha 4 integrin requires highest affinity integrin conformation, but is independent of post-translational modifications of osteopontin.

Authors:  Tommy Hui; Esben S Sørensen; Susan R Rittling
Journal:  Matrix Biol       Date:  2014-11-29       Impact factor: 11.583

6.  Osteopontin undergoes polymerization in vivo and gains chemotactic activity for neutrophils mediated by integrin alpha9beta1.

Authors:  Norihisa Nishimichi; Hiromi Hayashita-Kinoh; Chun Chen; Haruo Matsuda; Dean Sheppard; Yasuyuki Yokosaki
Journal:  J Biol Chem       Date:  2011-02-14       Impact factor: 5.157

7.  Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice.

Authors:  Dennis Bruemmer; Alan R Collins; Grace Noh; Wei Wang; Mary Territo; Sarah Arias-Magallona; Michael C Fishbein; Florian Blaschke; Ulrich Kintscher; Kristof Graf; Ronald E Law; Willa A Hsueh
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

8.  The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways.

Authors:  Donald Courter; Hongbin Cao; Shirley Kwok; Christina Kong; Alice Banh; Peiwen Kuo; Donna M Bouley; Carmen Vice; Odd Terje Brustugun; Nicholas C Denko; Albert C Koong; Amato Giaccia; Quynh-Thu Le
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

9.  Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells.

Authors:  Priyanka Sharma; Santosh Kumar; Gopal C Kundu
Journal:  Mol Cancer       Date:  2010-07-07       Impact factor: 27.401

10.  Osteopontin prevents monocyte recirculation and apoptosis.

Authors:  Tricia H Burdo; Malcolm R Wood; Howard S Fox
Journal:  J Leukoc Biol       Date:  2007-03-16       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.